Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339168 | 0.91 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1CA1CA2 | |
| SCHEMBL13014052 | 0.91 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1CA1CA2 | |
| SCHEMBL13589983 | 0.87 | CA1 (0.68) | ALDH1A1MAPK1L3MBTL1CA1CA2 | |
| SCHEMBL3093075 | 0.87 | CA1 (0.68) | ALDH1A1MAPK1L3MBTL1CA1CA2 | |
| SCHEMBL9162085 | 0.85 | CA1 (0.68) | ALDH1A1MAPK1L3MBTL1CA1CA2 | |
| SCHEMBL17879692 | 0.84 | CA1 (0.60) | ALDH1A1MAPK1L3MBTL1CA1CA2 | |
| SCHEMBL7571319 | 0.83 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1CA1CA2 | |
| SCHEMBL17879693 | 0.83 | CA1 (0.66) | ALDH1A1MAPK1L3MBTL1CA1CA2 | |
| SCHEMBL17879683 | 0.83 | CA1 (0.66) | ALDH1A1MAPK1L3MBTL1CA1CA2 | |
| SCHEMBL12191723 | 0.83 | CA1 (0.54) | ALDH1A1MAPK1L3MBTL1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001052899-A1 | CHELATING AGENTS AND METHOD FOR THEIR USE AS TANDEM METAL CHELATORS AND HYDROPHILIC SPACERS FOR MEDICAL DIAGNOSIS AND THERAPY | MALLINCKRODT INC. (US) | 2001-07-26 | — | — | WO | claimed |
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | CHONG, HYUN-SOON, PHD | 2017-01-12 | — | — | US | disclosed |
| US-9115094-B2 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | THE UNITED STATES OF AMERICA, NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) (US) | 2015-08-25 | — | — | US | disclosed |
| US-20100322855-A1 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2001052898-A9 | METHODS FOR INCORPORATING METAL CHELATORS AT CARBOXYL-TERMINAL SITE OF PEPTIDES | MALLINCKRODT INC (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2001052898-A1 | METHODS FOR INCORPORATING METAL CHELATORS AT CARBOXYL-TERMINAL SITE OF PEPTIDES | MALLINCKRODT INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001052900-A2 | NOVEL ORTHOGONALLY PROTECTED AMINO ACID CHELATORS FOR BIOMEDICAL APPLICATIONS | MALLINCKRODT INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6254850-B1 | POLYCARBOXYALKYLAMINOALKANES FOR COMPLEXES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-07-03 | — | — | US | disclosed |
| WO-2000058264-A1 | METHOD FOR THE SYNTHESIS OF NON-SYMMETRICAL DTPA COMPOUNDS | MALLINCKRODT INC. (US) | 2000-10-05 | — | — | WO | disclosed |
| US-6040432-A | Metal complexes, of DTPA derivatives suitable for use in diagnosis and therapy | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-21 | — | — | US | disclosed |
| EP-0810989-B1 | NOVELLY SUBSTITUTED DTPA DERIVATIVES, METAL COMPLEXES THEREOF, PHARMACEUTICALS CONTAINING THESE COMPLEXES, DIAGNOSTIC AND THERAPEUTIC USES THEREOF AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AG (DE) | 1999-08-04 | — | — | EP | disclosed |
| EP-0775104-B1 | DIMER DTPA DERIVATIVES AND THEIR METAL COMPLEXES, PHARMACEUTICALS CONTAINING THE SAME, THEIR USE IN DIAGNOSIS AND THERAPY AND PROCESS FOR PREPARING SAID COMPLEXES AND PHARMACEUTICALS | SCHERING AG (DE) | 1999-05-06 | — | — | EP | disclosed |
| EP-0810989-A1 | NOVELLY SUBSTITUTED DTPA DERIVATIVES, METAL COMPLEXES THEREOF, PHARMACEUTICALS CONTAINING THESE COMPLEXES, DIAGNOSTIC AND THERAPEUTIC USES THEREOF AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-10 | — | — | EP | disclosed |
| US-5695737-A | CONTRAST MEDIA FOR NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| EP-0775104-A1 | DIMER DTPA DERIVATIVES AND THEIR METAL COMPLEXES, PHARMACEUTICALS CONTAINING THE SAME, THEIR USE IN DIAGNOSIS AND THERAPY AND PROCESS FOR PREPARING SAID COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996026180-A1 | NOVELLY SUBSTITUTED DTPA DERIVATIVES, METAL COMPLEXES THEREOF, PHARMACEUTICALS CONTAINING THESE COMPLEXES, DIAGNOSTIC AND THERAPEUTIC USES THEREOF AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-08-29 | — | — | WO | disclosed |
| WO-1996005167-A1 | DIMER DTPA DERIVATIVES AND THEIR METAL COMPLEXES, PHARMACEUTICALS CONTAINING THE SAME, THEIR USE IN DIAGNOSIS AND THERAPY AND PROCESS FOR PREPARING SAID COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | AZI2, ABL1, DHPS | ALDH1A1 1847/4885MAPK1 4226/4885L3MBTL1 4881/4885 |
| US-20100322855-A1 | Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using | UACA, CLTC, PKD1 | ALDH1A1 3456/4885MAPK1 4408/4885L3MBTL1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.